Nasdaq issuer boosts $50M at-the-market stock plan
The company updates its at-the-market offering to cover up to $50,000,000 of common stock sold through A.G.P./Alliance Global Partners under an existing sales agreement.
Rhea-AI Filing Summary
The company updates its at-the-market offering to cover up to $50,000,000 of common stock sold through A.G.P./Alliance Global Partners under an existing sales agreement. This total includes $21,621,572.40 of common stock previously sold under the program.
The company states it is no longer subject to Form S-3 General Instruction I.B.6 because the market value of common stock held by non-affiliates was at least $75.0 million as of February 9, 2026. The common stock trades on Nasdaq under the symbol MNTS, with a last reported price of $6.44 per share on February 9, 2026.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the MNTS prospectus supplement change in the stock offering?
The prospectus supplement increases the at-the-market offering capacity to $50,000,000 of common stock. This updated amount includes $21,621,572.40 of shares already sold under the existing sales agreement with A.G.P./Alliance Global Partners.
How much common stock has MNTS already sold under the A.G.P. agreement?
The company has already sold $21,621,572.40 of common stock through A.G.P./Alliance Global Partners. This previously sold amount is part of, and not in addition to, the updated $50,000,000 total at-the-market offering capacity.
Why is Form S-3 General Instruction I.B.6 no longer applicable to MNTS?
Form S-3 General Instruction I.B.6 no longer applies because the aggregate market value of common stock held by non-affiliates reached at least $75.0 million as of February 9, 2026. This change affects prior limitations on the size of at-the-market offerings.
What role does A.G.P./Alliance Global Partners play in the MNTS offering?
A.G.P./Alliance Global Partners acts as sales agent or principal for the at-the-market program. It facilitates offers and sales of MNTS Class A common stock from time to time under the September 19, 2025 sales agreement referenced in the prospectus materials.
On which exchange is MNTS common stock listed and at what recent price?
The company’s common stock is listed on Nasdaq under the symbol MNTS. The last reported sale price was $6.44 per share on February 9, 2026, providing a recent market reference for the at-the-market stock offering.
What risks are highlighted for investors considering the MNTS stock offering?
The prospectus supplement directs investors to the “Risk Factors” section beginning on page S-12 of the prospectus and in incorporated documents. These sections describe the high degree of risk involved in investing in the company’s common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Filed Pursuant to Rule 424(b)(5)
Registration No. 333- 290425
PROSPECTUS SUPPLEMENT
(To Prospectus Supplement dated February 6, 2026)
(To Prospectus Supplement dated December 12, 2025)
(To Prospectus Supplement dated October 20, 2025)
(To Prospectus Supplement dated October 10, 2025)
(To Prospectus and Prospectus Supplement dated September 30, 2025)
Up to $50,000,000
of Common Stock
This prospectus supplement (the “Prospectus Supplement”) amends and supplements the prospectus supplement dated February 6, 2026, the prospectus supplement dated December 12, 2025, the prospectus supplement dated
October 20, 2025, the prospectus supplement dated October 10, 2025, the prospectus supplement dated September 30, 2025 and the accompanying base prospectus dated September 30, 2025 filed with the Securities and exchange Commission as part of our
registration statement on Form S-3 (collectively, the “ATM Prospectus”), relating to the offer and sale of shares of our Class A common stock, par value $0.00001 per share (“common stock” from time to time pursuant to the terms of the sales
agreement dated September 19, 2025 (the “ATM Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), acting as our sales agent or principal. This Prospectus Supplement should be read in conjunction with the ATM Prospectus, and is
qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the ATM Prospectus. This Prospectus Supplement is not complete without and may only be delivered or utilized in
connection with the ATM Prospectus, and any future amendments or supplements thereto.
We are filing this Prospectus Supplement to amend the ATM Prospectus to increase the amount of shares of common stock we may offer and sell through the Sales Agent pursuant to the ATM Agreement to $50,000,000, which
includes the $21,621,572.40 of shares of common stock that were previously sold pursuant to the ATM Agreement as of the date of this Prospectus Supplement.
We are no longer subject to General Instruction I.B.6. of Form S-3 as the aggregate market value of our common stock held by non-affiliates equaled or exceeded $75.0 million as of February 9, 2026. If we become
subject to the offering limitations contained in General Instruction I.B.6 of Form S-3 in the future, we will file another prospectus supplement.
Our common stock is listed on Nasdaq under the symbol “MNTS.” On February 9, 2026, the last reported sale price of our common stock on Nasdaq was $6.44 per share.
Investing in our common stock involves a high degree of risk. Before making an investment decision, please read the information under the heading “Risk Factors” beginning on
page S-12 of the ATM Prospectus and in the documents incorporated by reference into this prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any
representation to the contrary is a criminal offense.
A.G.P.
The date of this prospectus supplement is February 9, 2026